Effects of tirofiban combined with urokinase in patients with acute ST-elevation myocardial infarction

AIM: To study the efficacy and safety of tirofiban combined with urokinase in patients with acute ST-elevation myocardial infarction (STEMI). METHODS: Sixty consecutive STEMI patients were randomly divided into two groups: group A treated with urokinase 2 (n=24) and group B treated with tirofiban combined with urokinase (n=36). The efficacy of the treatment was compared between groups. RESULTS: Cardiovascular event rates, unstable angina, left ventricular ejection fraction and TMP in group B were better than those in group A (13.9% vs. 54.2%, 8.3% vs. 29.2%, 62.7±3.9 vs. 56.3±6.4, 72.2% vs. 41.7%, P<0.05). No significant difference was found in severe hemorrhage between groups. CONCLUSION: Tirofiban, a GPIIb/IIIa antagonist, is safe and effective when administered in combination with urokinase in STEMI patients.